



## PRESS RELEASE

### THE BOARD OF DIRECTORS OF PIERREL S.P.A.

- ✓ Appoints a manager for the *Internal Audit* function
- ✓ Appoints an Audit Committee with a sole member

Capua, 15 July 2015 – The Board of Directors of Pierrel S.p.A. (“**Pierrel**” or the “**Company**”) meeting today, noted that the term of office of Renato Esposito as the *Internal Auditor* in *co-sourcing* for the Company had expired, appointed Vittorio Gennaro, CEO of Operari S.r.l., as manager of the *internal audit* function in *outsourcing* for Pierrel.

The Board noted the resignation of the Audit Committee previously in office, and also decided to establish and appoint an Audit Committee pursuant to Legislative Decree 231/2001 with a sole member, by appointing as sole member of the Committee Camilla Calzone, associate advocate at Operari Lex- Studio Legale Associato.

Dr Gennaro and the advocate Mr Calzone remain in office until the date of approval of the draft financial statements of the Company at 31 December 2018.

The *curricula vitae* of Dr Gennaro and the advocate Mr Calzone are available on the web site of the Company at [www.pierrelgroup.com](http://www.pierrelgroup.com).

\* \* \*

**Pierrel S.p.A.** is a global supplier to the pharmaceutical, biopharmaceutical and life science industries, specialising in the discovery of medicinal product candidates and the repositioning of existing drugs for new therapeutic indications and clinical research (TCRDO Division), pharmaceutical production (Contract Manufacturing Division) and the development, registration and licensing of new drugs and medical devices (Pharma Division).

Pierrel Group is listed on the MTA exchange which is organised and managed by Borsa Italiana and boasts over 60 years’ experience in the pharmaceutical sector, being one of Europe’s leading producers of local and dental anaesthetics. The TCRDO Division, working across Europe and the US, is recognised internationally for its research and development into tech based clinical research innovations with its Drug Repositioning and Repurposing System (“DRR2.0”) and Integrated Clinical Development Services (“ICDS”) for the pharmaceutical, biotechnology and biomedical industries. The parent company of the TCRDO Division (**THERAMetrics holding AG**, listed in the Swiss stock exchange) holds the innovative interactive **DRR2.0** platform, which runs on a database of 24 million scientific publications (being virtually all of those available in the field of biomedical literature), of over 4,900 drugs and of 9,400 illnesses. With this data, never before collected in one place and stored in the cloud, the Search and Match algorithm can show a researcher not only the candidate drug but also a detailed road map with indications of possible second medical uses. The database can be searched by molecule or by illness. Pierrel also has a production unit in Capua, close to Naples, Italy, that has been authorised by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) for the aseptic production of injectable medicines. The subsidiary Pierrel Pharma S.r.l. has registered and distributes the Orabloc® dental anaesthetic in Canada, US, Russia and Europe.

The registered office of Pierrel S.p.A. is in Capua (CE), Italy.

#### For further information:

##### **Pierrel S.p.A.**

*Investor Relations*

Dr Raffaele Petrone

*e-mail:*

[investor.relations@pierrelgroup.com](mailto:investor.relations@pierrelgroup.com)

tel. +39 0823 626 111

fax +39 0823 626 228

##### **Global Consult S.r.l.**

*Media Relations*

Rossana Del Forno

*e-mail:*

[areacomunicazione@globalconsultsrl.com](mailto:areacomunicazione@globalconsultsrl.com)

tel. +39 333 6178665

